The National Committee for Newborn Screening in Spinal Muscular Atrophy (Australia and New Zealand) consulted on the draft National Recommendations for Newborn Screening in Spinal Muscular Atrophy in Australia and New Zealand, which provides guidance for screening, diagnosis and care in the process of newborn screening for newborns and infants with spinal muscular atrophy (SMA). Australian Genomics’ response included support for the draft recommendations while highlighting the need for formal representation of Aboriginal and Torres Strait Islander, Pacific Islander and/or Māori populations in the development of the recommendations.
